Skip to main content
. 2014 Mar 6;2:26. doi: 10.1186/2051-5960-2-26

Table 1.

CN ADNI subjects included in the longitudinal study

 
 ADNI-1
 ADNI-GO/2
 CN stable ADNI-1 vs. ADNI-GO/2
  CN stable (n = 120) CN progressors (n = 35) p-value CN stable (n = 163) CN progressors (n = 8) p-value p-value
Progression to
 -
 29 MCI
 -
 -
 7 MCI
 -
  
6 AD
 1 AD
Age at baseline (years)
 74.9 (72.0-78.5)
 77.0 (73.0-79.2)
 0.37
 72.6 (69.4-77.1)
 83.0 (80.4-84.8)
 0.0001
 0.0001
Gender (% male)
 52.5%
 57.1%
 0.49
 50.9%
 75.0%
 0.28
 0.89
Education (years)
 16.0 (14.0-18.0)
 16.0 (13.0-18.0)
 0.52
 16.0 (15.0-18.5)
 17.0 (13.8-18.5)
 0.86
 0.060
APOE ϵ4 presence
 22.5%
 31.4%
 0.39
 29.5%
 12.5%
 0.44
 0.22
ADAS-Cog
 9.33 (6.0-12.3)
 10.8 (8.6-13.3)
 0.047
 9.0 (6.0-11)
 15.0 (13.5-16.5)
 0.0003
 0.31
Memory summary score
 0.94 (0.66-1.37)
 0.71 (0.44-1.01)
 0.006
 0.94 (0.55-1.22)
 0.22 (0.02-0.42)
 0.0004
 0.16
Executive summary score
 0.66 (0.29-1.22)
 0.40 (0.03-0.77)
 0.039
 0.82 (0.40-1.44)
 0.23 [(−0.15)-0.47]
 0.004
 0.091
aHV1
 812.0 (347.3-1244.5)
 586.8 (94.5-1322.6)]
 0.25
 529.8 (9.0-1085.3)
 −226.1 [(−419.3)-(6.7)]
 0.007
 0.015
SPARE-AD
 −1.44 [(−2.15)-(−0.99)]
 −1.17 [(−1.74)-(−0.68)]
 0.053
 −1.32 [(−1.61)-(−1.07)]
 −0.90 [(−1.04)-(−0.30)]
 0.029
 0.019
HCI
 5.3 (3.3-7.5)
 6.0 (3.9-8.7)
 0.20
 5.5 (3.5-7.7)
 7.2 (3.5-13.6)
 0.051
 0.29
PC-FDG-PET
 1.38 (1.29-1.53)
 1.29 (1.23-1.43)
 0.022
 1.45 (1.33-1.51)
 1.31 (1.20-1.36)
 0.014
 0.54
Aβ1–42 (pg/ml)
 222.0 (163.5-257.0)
 210.0 (144.5-235.0)
 0.25
 207.7 (158.3-237.3)
 147.8 (108.2-205.7)
 0.083
 0.065
T-tau (pg/ml)
 60.0 (47.5-80.8)
 71.5 (54.3-95.3)
 0.13
 56.3 (45.6-81.0)
 111.5 (93.7-123.4)
 0.032
 0.53
P-tau181 (pg/ml) 20.0 (16.0-27.5) 22.0 (17.0-31.5) 0.36 30.0 (21.9-43.1) 35.6 (31.0-44.0) 0.25 <0.0001

aHV = adjusted hippocampal volume.

1Adjusted for intracranial volume.

Median (1st quartile-3rd quartile).